1. Scrip

Demand for non-clinical development support drives L2D expansion

 
• By Sukaina Virji

An increase in demand from small- and medium-sized drug development companies for non-clinical development support has led to one young CRO, Leads to Development (L2D), opening new two new offices alongside its Paris, France base.

An increase in demand from small- and medium-sized drug development companies for non-clinical development support has led to one young CRO, Leads to Development (L2D), opening new two new offices alongside its Paris, France base.

L2D was founded last year by executives from former French biotech firm Diatos, which had to shut up shop after...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.